Troponin, cardiac muscle
Complex in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
- Genes: 3
Who is on it, and how far along
Every drug ChEMBL records acting on TNNC1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Levosimendan | Phase 3 | Tenax Therapeutics | Small molecule | Positive modulatorTroponin, cardiac muscle positive modulator | 9 |
| The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy | Levosimendan | Not applicable | Recruiting | Meshalkin Research Institute of Pathology of Circulation | Nov 4, 2026 |
| Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study | Levosimendan | Not applicable | Recruiting | Niguarda Hospital | Jun 24, 2026 |
| Long-Term Open-Label Extension Study of Oral Levosimendan | Levosimendan | Phase 3 | Enrolling by invitation | Tenax Therapeutics, Inc. | Feb 27, 2026 |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Levosimendan | Phase 3 | Active, not recruiting | Tenax Therapeutics, Inc. | Dec 17, 2025 |
| Levosimendan in Acute Decompensated Heart Failure | Levosimendan | Phase 2 / Phase 3 | Not yet recruiting | Chittagong Medical College | Dec 4, 2025 |
| Shorter Weaning From Invasive Ventilation With Levosimendan | Levosimendan | Phase 4 | Recruiting | Radboud University Medical Center | Aug 5, 2025 |
| Pharmacokinetic Modelling of Levosimendan in Adults | Levosimendan | — | Not yet recruiting | University Hospital, Rouen | May 29, 2025 |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Levosimendan | Phase 3 | Active, not recruiting | Tenax Therapeutics, Inc. | Aug 9, 2023 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095202, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets